| Theme |
Cirrhosis -- Recent Progress in Diagnosis and Treatmen |
| Title |
Current Status of and Prospects for Liver Regeneration Therapy Using Bone Marrow-Derived Cells |
| Author |
Shogo Shiratsuki |
Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine |
| Author |
Taro Takami |
Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine |
| Author |
Shuji Terai |
Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine |
| Author |
Isao Sakaida |
Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine |
| [ Summary ] |
Liver regeneration therapy has attracted attention as a new therapy for patients with cirrhotic conditions. Various clinical studies on liver cirrhosis have been reported, including hepatic administration of autologous CD34-positive cells induced by granulocyte colony-stimulating factor, and administration of autologous bone marrow-derived cells. The effectiveness of these approaches has been shown in some patients. Improved liver fibrosis and function after infusion of whole bone marrow cells has been observed in basic studies using murine cirrhotic models. On the basis of those results, we developed autologous bone marrow cell infusion (ABMi) therapy for liver cirrhosis. The efficacy and safety of this approach has been demonstrated. Furthermore, a study on the efficacy and safety of ABMi therapy for patients with cirrhotic hepatitis C with viral origins was approved as an advanced medical treatment B in June 2013. The current status of and prospects for liver regeneration therapies using bone marrow-derived cells are presented. |